# Adma Biologics, Inc.: financial statements, quarterly ADMA · Nasdaq · CIK 1368514 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/adma.md) · [Financials](/companies/adma/financials.md) · [Filings](/companies/adma/filings.md) · [Insiders](/companies/adma/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adma/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [67.3](/filings/0001140361-24-045693.md) | [73.9 d](/filings/0001140361-26-006815.md) | [81.9](/filings/0001140361-25-017747.md) | [107](/filings/0001140361-25-029177.md) | [120](/filings/0001140361-25-040578.md) | [118 d](/filings/0001140361-26-006815.md) | [115](/filings/0001140361-26-019336.md) | [122](/filings/0001140361-26-031445.md) | [134](/filings/0001140361-25-040578.md) | [139 d](/filings/0001140361-26-006815.md) | [114](/filings/0001140361-26-019336.md) | [124](/filings/0001140361-26-031445.md) | | Cost of revenue | $m | [42.6](/filings/0001140361-24-045693.md) | [42.8 d](/filings/0001140361-26-006815.md) | [42.8](/filings/0001140361-25-017747.md) | [49.7](/filings/0001140361-25-029177.md) | [60.2](/filings/0001140361-25-040578.md) | [54.2 d](/filings/0001140361-26-006815.md) | [53.7](/filings/0001140361-26-019336.md) | [54.8](/filings/0001140361-26-031445.md) | [58.6](/filings/0001140361-25-040578.md) | [50.3 d](/filings/0001140361-26-006815.md) | [33.7](/filings/0001140361-26-019336.md) | [38.1](/filings/0001140361-26-031445.md) | | Gross profit | $m | [24.7](/filings/0001140361-24-045693.md) | [31.1 d](/filings/0001140361-26-006815.md) | [39.1](/filings/0001140361-25-017747.md) | [57.5](/filings/0001140361-25-029177.md) | [59.7](/filings/0001140361-25-040578.md) | [63.3 d](/filings/0001140361-26-006815.md) | [61.1](/filings/0001140361-26-019336.md) | [67.2](/filings/0001140361-26-031445.md) | [75.6](/filings/0001140361-25-040578.md) | [88.8 d](/filings/0001140361-26-006815.md) | [80.8](/filings/0001140361-26-019336.md) | [86.3](/filings/0001140361-26-031445.md) | | Research and development | $m | [0.6](/filings/0001140361-24-045693.md) | [0.4 d](/filings/0001140361-26-006815.md) | [0.5](/filings/0001140361-25-017747.md) | [0.6](/filings/0001140361-25-029177.md) | [0.4](/filings/0001140361-25-040578.md) | [0.4 d](/filings/0001140361-26-006815.md) | [0.8](/filings/0001140361-26-019336.md) | [1.0](/filings/0001140361-26-031445.md) | [1.5](/filings/0001140361-25-040578.md) | [1.4 d](/filings/0001140361-26-006815.md) | [2.6](/filings/0001140361-26-019336.md) | [6.0](/filings/0001140361-26-031445.md) | | Selling, general and administrative | $m | [14.7](/filings/0001140361-24-045693.md) | [15.5 d](/filings/0001140361-26-006815.md) | [15.6](/filings/0001140361-25-017747.md) | [16.6](/filings/0001140361-25-029177.md) | [18.6](/filings/0001140361-25-040578.md) | [23.3 d](/filings/0001140361-26-006815.md) | [24.1](/filings/0001140361-26-019336.md) | [22.2](/filings/0001140361-26-031445.md) | [21.8](/filings/0001140361-25-040578.md) | [23.5 d](/filings/0001140361-26-006815.md) | [26.7](/filings/0001140361-26-019336.md) | [26.7](/filings/0001140361-26-031445.md) | | Operating income | $m | [8.7](/filings/0001140361-24-045693.md) | [14.2 d](/filings/0001140361-26-006815.md) | [21.8](/filings/0001140361-25-017747.md) | [39.2](/filings/0001140361-25-029177.md) | [39.6](/filings/0001140361-25-040578.md) | [38.3 d](/filings/0001140361-26-006815.md) | [34.9](/filings/0001140361-26-019336.md) | [42.8](/filings/0001140361-26-031445.md) | [51.0](/filings/0001140361-25-040578.md) | [62.8 d](/filings/0001140361-26-006815.md) | [58.3](/filings/0001140361-26-019336.md) | [52.4](/filings/0001140361-26-031445.md) | | Interest expense | $m | [6.4](/filings/0001140361-23-052109.md) | [6.2 d](/filings/0001140361-24-010147.md) | [3.8](/filings/0001140361-24-025226.md) | [3.8](/filings/0001140361-25-029177.md) | [3.5](/filings/0001140361-25-040578.md) | [2.9 d](/filings/0001140361-26-006815.md) | [2.0](/filings/0001140361-26-019336.md) | [1.8](/filings/0001140361-26-031445.md) | [1.7](/filings/0001140361-25-040578.md) | [1.6 d](/filings/0001140361-26-006815.md) | [2.1](/filings/0001140361-26-019336.md) | [3.4](/filings/0001140361-26-031445.md) | | Income tax | $m | [0.0](/filings/0001140361-24-045693.md) | [0.0 d](/filings/0001140361-26-006815.md) | [0.6](/filings/0001140361-25-017747.md) | [3.8](/filings/0001140361-25-029177.md) | [0.8](/filings/0001140361-25-040578.md) | [(77.2) d](/filings/0001140361-26-006815.md) | [6.5](/filings/0001140361-26-019336.md) | [5.9](/filings/0001140361-26-031445.md) | [11.1](/filings/0001140361-25-040578.md) | [12.2 d](/filings/0001140361-26-006815.md) | [11.8](/filings/0001140361-26-019336.md) | [12.4](/filings/0001140361-26-031445.md) | | Net income | $m | [2.6](/filings/0001140361-24-045693.md) | [(17.6) d](/filings/0001140361-26-006815.md) | [17.8](/filings/0001140361-25-040578.md) | [32.1](/filings/0001140361-25-040578.md) | [35.9](/filings/0001140361-25-040578.md) | [112 d](/filings/0001140361-26-006815.md) | [26.9](/filings/0001140361-26-031445.md) | [34.2](/filings/0001140361-26-031445.md) | [36.4](/filings/0001140361-25-040578.md) | [49.4 d](/filings/0001140361-26-006815.md) | [45.3](/filings/0001140361-26-031445.md) | [37.8](/filings/0001140361-26-031445.md) | | Diluted EPS | $ per share | [0.01](/filings/0001140361-24-045693.md) | not reported | [0.08](/filings/0001140361-25-017747.md) | [0.13](/filings/0001140361-25-029177.md) | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.11](/filings/0001140361-26-019336.md) | [0.14](/filings/0001140361-26-031445.md) | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.19](/filings/0001140361-26-019336.md) | [0.16](/filings/0001140361-26-031445.md) | | Basic EPS | $ per share | [0.01](/filings/0001140361-24-045693.md) | not reported | [0.08](/filings/0001140361-25-017747.md) | [0.14](/filings/0001140361-25-029177.md) | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.11](/filings/0001140361-26-019336.md) | [0.14](/filings/0001140361-26-031445.md) | [0.15](/filings/0001140361-25-040578.md) | not reported | [0.19](/filings/0001140361-26-019336.md) | [0.17](/filings/0001140361-26-031445.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [74.2](/filings/0001140361-23-052109.md) | [51.4](/filings/0001140361-25-009257.md) | [45.3](/filings/0001140361-24-025226.md) | [88.2](/filings/0001140361-24-036432.md) | [86.7](/filings/0001140361-24-045693.md) | [103](/filings/0001140361-26-006815.md) | [71.6](/filings/0001140361-25-017747.md) | [90.3](/filings/0001140361-25-029177.md) | [61.4](/filings/0001140361-25-040578.md) | [87.6](/filings/0001140361-26-031445.md) | [138](/filings/0001140361-26-019336.md) | [136](/filings/0001140361-26-031445.md) | | Current assets | $m | [274](/filings/0001140361-23-052109.md) | [257](/filings/0001140361-25-009257.md) | [276](/filings/0001140361-24-025226.md) | [304](/filings/0001140361-24-036432.md) | [318](/filings/0001140361-24-045693.md) | [331](/filings/0001140361-26-006815.md) | [352](/filings/0001140361-25-017747.md) | [400](/filings/0001140361-25-029177.md) | [403](/filings/0001140361-25-040578.md) | [467](/filings/0001140361-26-031445.md) | [511](/filings/0001140361-26-019336.md) | [528](/filings/0001140361-26-031445.md) | | Total assets | $m | [349](/filings/0001140361-24-045693.md) | [329](/filings/0001140361-26-006815.md) | [351](/filings/0001140361-25-017747.md) | [376](/filings/0001140361-25-029177.md) | [391](/filings/0001140361-25-040578.md) | [489](/filings/0001140361-26-006815.md) | [511](/filings/0001140361-26-019336.md) | [558](/filings/0001140361-26-031445.md) | [569](/filings/0001140361-25-040578.md) | [624](/filings/0001140361-26-031445.md) | [665](/filings/0001140361-26-019336.md) | [684](/filings/0001140361-26-031445.md) | | Current liabilities | $m | [41.8](/filings/0001140361-23-052109.md) | [49.8](/filings/0001140361-25-009257.md) | [53.1](/filings/0001140361-24-025226.md) | [44.2](/filings/0001140361-24-036432.md) | [44.9](/filings/0001140361-24-045693.md) | [55.5](/filings/0001140361-26-006815.md) | [53.5](/filings/0001140361-25-017747.md) | [74.9](/filings/0001140361-25-029177.md) | [56.5](/filings/0001140361-25-040578.md) | [69.5](/filings/0001140361-26-031445.md) | [73.5](/filings/0001140361-26-019336.md) | [75.8](/filings/0001140361-26-031445.md) | | Total liabilities | $m | [198](/filings/0001140361-23-052109.md) | [194](/filings/0001140361-25-009257.md) | [197](/filings/0001140361-24-025226.md) | [188](/filings/0001140361-24-036432.md) | [159](/filings/0001140361-24-045693.md) | [140](/filings/0001140361-26-006815.md) | [137](/filings/0001140361-25-017747.md) | [160](/filings/0001140361-25-029177.md) | [138](/filings/0001140361-25-040578.md) | [147](/filings/0001140361-26-031445.md) | [275](/filings/0001140361-26-019336.md) | [276](/filings/0001140361-26-031445.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [72.3](/filings/0001140361-26-006815.md) | not reported | not reported | [70.1](/filings/0001140361-25-040578.md) | [69.3](/filings/0001140361-26-031445.md) | [194](/filings/0001140361-26-019336.md) | [193](/filings/0001140361-26-031445.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001140361-26-006815.md) | not reported | not reported | [2.3](/filings/0001140361-25-040578.md) | [2.8](/filings/0001140361-26-031445.md) | [3.3](/filings/0001140361-26-019336.md) | [3.8](/filings/0001140361-26-031445.md) | | Shareholders' equity | $m | [151](/filings/0001140361-24-045693.md) | [135](/filings/0001140361-26-006815.md) | [154](/filings/0001140361-25-040578.md) | [188](/filings/0001140361-25-040578.md) | [232](/filings/0001140361-25-040578.md) | [349](/filings/0001140361-26-031445.md) | [373](/filings/0001140361-26-031445.md) | [398](/filings/0001140361-26-031445.md) | [431](/filings/0001140361-25-040578.md) | [477](/filings/0001140361-26-031445.md) | [390](/filings/0001140361-26-031445.md) | [408](/filings/0001140361-26-031445.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [12.0 d](/filings/0001140361-24-045693.md) | [17.6 d](/filings/0001140361-26-006815.md) | [(2.2)](/filings/0001140361-25-017747.md) | [45.6 d](/filings/0001140361-25-029177.md) | [25.0 d](/filings/0001140361-25-040578.md) | [50.2 d](/filings/0001140361-26-006815.md) | [(19.7)](/filings/0001140361-26-019336.md) | [21.1 d](/filings/0001140361-26-031445.md) | [13.3 d](/filings/0001140361-25-040578.md) | [35.6 d](/filings/0001140361-26-006815.md) | [58.2](/filings/0001140361-26-019336.md) | [29.5 d](/filings/0001140361-26-031445.md) | | Capital expenditure | $m | [0.8 d](/filings/0001140361-24-045693.md) | [1.2 d](/filings/0001140361-26-006815.md) | [2.3](/filings/0001140361-25-017747.md) | [2.1 d](/filings/0001140361-25-029177.md) | [1.1 d](/filings/0001140361-25-040578.md) | [2.8 d](/filings/0001140361-26-006815.md) | [4.7](/filings/0001140361-26-019336.md) | [2.4 d](/filings/0001140361-26-031445.md) | [14.4 d](/filings/0001140361-25-040578.md) | [1.1 d](/filings/0001140361-26-006815.md) | [2.5](/filings/0001140361-26-019336.md) | [2.3 d](/filings/0001140361-26-031445.md) | | Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001140361-26-006815.md) | [0.0](/filings/0001140361-26-019336.md) | [0.0 d](/filings/0001140361-26-031445.md) | [23.0 d](/filings/0001140361-25-040578.md) | [8.9 d](/filings/0001140361-26-006815.md) | [130](/filings/0001140361-26-019336.md) | [25.1 d](/filings/0001140361-26-031445.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [196](/filings/0001140361-23-052109.md) | [222](/filings/0001140361-24-025226.md) | [223](/filings/0001140361-24-036432.md) | [234](/filings/0001140361-24-045693.md) | [236](/filings/0001140361-25-017747.md) | [242](/filings/0001140361-25-029177.md) | [245](/filings/0001140361-25-040578.md) | [245](/filings/0001140361-26-019336.md) | [249](/filings/0001140361-26-031445.md) | [245](/filings/0001140361-25-040578.md) | [240](/filings/0001140361-26-019336.md) | [230](/filings/0001140361-26-031445.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 223,984,680 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001140361-26-031445.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.